Navigation Links
Genzyme Delivers Strong Fourth Quarter to Conclude Outstanding Year
Date:2/13/2008

of our

investment in the common stock of Cambridge Antibody Technology Group

plc in May and June 2006.

(9) Includes charges totaling $(5,735)K recorded in December 2007 to

write off costs associated with the manufacture of tolevamer at our

manufacturing facilities in Ireland and the United Kingdom.

(10) All periods except for the three months and year ended December 31,

2006, reflect the adoption of Emerging Issues Task Force Issue No.

04-8, "The Effect of Contingently Convertible Debt on Diluted

Earnings Per Share," or EITF 04-8. As a result of the adoption of

EITF 04-8, the 9,686K shares issuable upon conversion of our $690.0

million in principal of 1.25% convertible senior notes, which were

issued in December 2003, are now included in diluted weighted average

shares outstanding for purposes of computing diluted earnings per

share, unless the effect would be anti-dilutive. In accordance with

EITF 04-8, interest and debt fees related to these notes of $1.9

million, net of tax, for the three months ended December 31, 2007 and

$7.5 million, net of tax, for the twelve months ended December 31,

2007, have been added back to net income and 9,686K shares have been

added to diluted weighted average shares outstanding for each of

those periods for purposes of computing diluted earnings per share.

For the three months and year ended December 31, 2006, excludes: (i)

the dilutive effect of options, stock purchase rights and warrants to

purchase shares of Genzyme Stock and (ii) the potentially dilutive

effect of the assumed conversion of our convertible senior notes

because the effect would be anti-dilutive due to our net loss for

both of those periods.

GENZYME CORPORATION (GENZ)

Conden
'/>"/>

SOURCE Genzyme Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24

Related medicine news :

1. Genzyme Receives FDA Response Letter on Synvisc-One(TM)
2. Bioenvision Shareholders Approve Acquisition by Genzyme Corporation
3. Genzyme Statement Regarding Results of FDA Advisory Committee Meeting on the Use of Phosphate Binders in Chronic Kidney Disease
4. Genzyme and Bayer Schering Pharma AG, Germany to Present New Data on Alemtuzumab in Multiple Sclerosis at ECTRIMS
5. Delaware Court Approves Bioenvision, Genzyme Joint Petition
6. Elliott Extremely Dissatisfied With Genzyme Bid for Bioenvision; Believes Offer Significantly Undervalues Company
7. Liquent Insight Publisher 3.6 Delivers Advanced Submission Capabilities
8. March of Dimes Delivers a New Look
9. Independence Blue Cross Delivers Important Reminder to Women during Cervical Cancer Awareness Month
10. PARIs eFlow Delivers Alnylam RNAi Therapeutic in Phase I Study
11. Gleevec, the targeted cancer pill, delivers more good news to patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... June 19, 2013 Over the past ... Retailer industry has been growing at an annualized ... 2013. Many factors have supported the development of the ... retailed by drugstores; relatively higher drug prices in hospitals; ... government's support for the development of chain drug retailing ...
(Date:6/18/2013)... Chicago, IL (PRWEB) June 18, 2013 Exposed ... is helping thousands of acne suffers of all ages finally ... Unlike other acne treatment products, this new acne clearing system ... current acne, and prevent new acne from forming. ... , ExposedSkinCareReview.org believes these products are some of the most ...
(Date:6/18/2013)... Fla. (PRWEB) June 19, 2013 An ... When Linda Christina Beauregard was diagnosed with breast cancer, ... In her new book, “I Gave Myself Cancer, I ... Life” (published by Balboa Press), Beauregard explains how changing ... cancer. , "Sick people have been made to feel ...
(Date:6/18/2013)... Vienna, VA (PRWEB) June 18, 2013 As ... the increase in need for surgical equipment during childbirth comes ... the child from within the mother when she is unable ... difficult deliveries, they are associated with higher rates of complication ... addition to being harmful to the mother and child, forceps ...
(Date:6/18/2013)... Parker Waichman LLP , a ... victims injured by defective medical devices, reports that the ... bone graft products are now available. Published this week ... two studies serve up two key findings: There is ... and the traditional bone graft; and there is “substantial ...
Breaking Medicine News(10 mins):Health News:Pharmacies and Drug Retailers in China Industry Research Report – Now Available from IBISWorld 2Health News:Pharmacies and Drug Retailers in China Industry Research Report – Now Available from IBISWorld 3Health News:Exposed Skin Care Review Released by ExposedSkinCareReview.org 2Health News:Exposed Skin Care Review Released by ExposedSkinCareReview.org 3Health News:Cancer Survivor Linda Christina Beauregard Writes New Tell-All Book About Her Alternative Treatment Method 2Health News:Forceps Births Double, Obesity is Major Reason in Births Complications 2Health News:Yale Releases the Findings of the Medtronic-Commissioned Infuse Bone Graft Study; Parker Waichman LLP Comments 2Health News:Yale Releases the Findings of the Medtronic-Commissioned Infuse Bone Graft Study; Parker Waichman LLP Comments 3
... , DUQUESNE, Pa., Sept. 22 Wherever you live, ... house. From pulling out blankets, replacing smoke detector batteries, varying the ... their home routines in the fall. , , ... , If you are one of the estimated 40-50 ...
... INDIANAPOLIS, Sept. 22 Eli Lilly and Company (NYSE: ... Lilly China, has been promoted to president, Lilly USA, LLC. Ricks ... Business Unit as part of a company reorganization announced Sept. 14. , ... to lead Lilly USA, which is considered Lilly,s largest established market. , ...
... SALEM, N.H., Sept. 22 ALPCO is pleased ... easy and accurate measurement of both active (7-36) GLP-1 ... , , GLP-1, an incretin hormone, has been a focus ... was approved by the FDA in 2006, and early clinical data demonstrates that ...
... Results from Australia,s largest study of young drivers have shown ... roads. According to researchers from The George Institute, young drivers ... in serious crashes than those in urban areas. ... today at the launch of the Young Driver Factbase ...
... HATBORO, Pa., Sept. 22 InfoLogix, Inc. (Nasdaq: ... for the healthcare and commercial industries, announced today that it ... a private, not-for-profit healthcare system serving the greater Philadelphia area, ... large-scale Electronic Medical Record (EMR) implementation. , , ...
... , , DURHAM, N.C., Sept. 22 ... chairman and CEO, Chris Stern, will present at an investor conferences in ... will be at the Zurich Airport Radisson Hotel and is scheduled for ... be open to interested investors. , , ...
Cached Medicine News:Health News:'Flip for Fall' Seasonal Household Tips Include Ten Million Reasons to Use Allergy-Protective Bedding 2Health News:'Flip for Fall' Seasonal Household Tips Include Ten Million Reasons to Use Allergy-Protective Bedding 3Health News:Lilly Announces New U.S. Affiliate Leader 2Health News:ALPCO Launches GLP-1 (Active 7-36) and (7-36 and 9-36) ELISA Kits 2Health News:Rural roads dangerous for young drivers 2Health News:InfoLogix Selected by Albert Einstein Healthcare Network for eLearning Modules to Support EMR Implementation 2Health News:InfoLogix Selected by Albert Einstein Healthcare Network for eLearning Modules to Support EMR Implementation 3
(Date:6/18/2013)... HILL, N.C. , June 18, 2013  Recent ... more difficult for Medical Education groups at large pharmaceutical ... on the safe and effective use of their new ... the pharma industry, it is crucial that these ... reaching healthcare professionals. To address the changes ...
(Date:6/18/2013)... , June 18, 2013  Women are frequently ... but unfortunately they often do not give the same ... have kept information from their doctor because they were ... according to a recent survey conducted by Allergan and ... dedicated to bringing education, funding and research to the ...
(Date:6/18/2013)... The board of directors of Eli Lilly ... a dividend for the third quarter of 2013 of ... The dividend is payable September 10, 2013 to ... August 15, 2013. Lilly, a leading innovation-driven ... by applying the latest research from its own worldwide ...
Breaking Medicine Technology:Though Vital to Educating Doctors on New Products, Pharma "Med Ed" Groups Working Under Huge Internal & External Constraints 2New Survey Reveals One in Five Women Have Information They Keep Secret from their Doctors 2New Survey Reveals One in Five Women Have Information They Keep Secret from their Doctors 3New Survey Reveals One in Five Women Have Information They Keep Secret from their Doctors 4New Survey Reveals One in Five Women Have Information They Keep Secret from their Doctors 5New Survey Reveals One in Five Women Have Information They Keep Secret from their Doctors 6New Survey Reveals One in Five Women Have Information They Keep Secret from their Doctors 7New Survey Reveals One in Five Women Have Information They Keep Secret from their Doctors 8New Survey Reveals One in Five Women Have Information They Keep Secret from their Doctors 9
... RATE- MEDIAN SURVIVAL OF 10.5 MONTHS IN COMPLETE ... MEETINGSOUTH SAN FRANCISCO, Calif., March 3 Hana ... new positive preliminary efficacy results from a planned ... trial evaluating Marqibo(R) (vincristine sulfate liposomes injection) for ...
... Society of Gynecologic Oncologists (SGO) and the American College ... breast disease fellowship training program for gynecologic oncologists. ... program provides support for a gynecologic oncologist to complete ... of breast cancer and related disease. "As experts ...
Cached Medicine Technology:Hana Biosciences Announces New Positive Interim Efficacy Results in Pivotal rALLy Clinical Trial of Marqibo in Acute Lymphoblastic Leukemia 2Hana Biosciences Announces New Positive Interim Efficacy Results in Pivotal rALLy Clinical Trial of Marqibo in Acute Lymphoblastic Leukemia 3Hana Biosciences Announces New Positive Interim Efficacy Results in Pivotal rALLy Clinical Trial of Marqibo in Acute Lymphoblastic Leukemia 4Hana Biosciences Announces New Positive Interim Efficacy Results in Pivotal rALLy Clinical Trial of Marqibo in Acute Lymphoblastic Leukemia 5SGO and ACOG Announce Breast Cancer Fellowship Program for Gynecologic Oncologists 2SGO and ACOG Announce Breast Cancer Fellowship Program for Gynecologic Oncologists 3
Tendril DX active-fixation leads allows for lower thresholds initially and during the lead maturation phase....
... Guidant Flextend lead is ... lead with an extendable/retractable ... helix design offers various ... permanent implantation in the ...
... PY series leads are implantable bipolar ... stimulation of either the atrium or ... screw can be extended or retracted ... lead tip contains an anti-chattering mechanism ...
Used with permanent pacing leads....
Medicine Products: